Ventria Defeats Wuhan Healthgen Challenge to Cell Culture Patent

Ventria Bioscience Inc. convinced a US Patent and Trademark Office administrative tribunal to uphold its patent related to cell culture formulation that comes from rice.

China-based Wuhan Healthgen Biotechnology Corp. failed to demonstrate a sufficient likelihood that Ventria’s US Patent No. 11,492,389 was obvious, and the request for a patent review was declined on Monday by the Patent Trial and Appeal Board. Wuhan Healthgen sought to invalidate the invention after the International Trade Commission blocked imports of its clinical-grade, genetically-engineered rice seeds in 2022 for infringing a related patent.

Albumin is a protein that can be derived from different sources ...